AbbVie and C2N Enter into a Worldwide License Agreement
News Mar 27, 2015
AbbVie has announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. This partnership builds upon AbbVie's commitment to pursue transformational disease-modifying therapies in Alzheimer's Disease.
Tau stabilizes proteins that are responsible for the structure and transport in neuronal cells.
Abnormal accumulation of altered tau protein is a leading indicator in a variety of neurodegenerative conditions including Alzheimer's Disease, Progressive Supranuclear Palsy and Corticobasal Degeneration. In these conditions, the development of tau pathology strongly correlates with clinical disease progression.
"The need for new approaches and therapies to address Alzheimer's disease is critical," said Jim Sullivan, Ph.D., vice president, pharmaceutical discovery, AbbVie.
Sullivan continued, "C2N's portfolio of anti-tau antibodies represents one of the most promising approaches to delaying progression of devastating neurodegenerative disease. Combining the world class expertise in Alzheimer's Disease at C2N with AbbVie's proven capabilities in neuroscience will enable the rapid advancement of anti-tau antibodies into patients."
Doctors Rely on More Than Just Data During a DiagnosisNews
Computer scientists examine how a doctor’s “gut feeling” influences how many tests they order for patientsREAD MORE
Working Together Helps Phage Overcome CRISPRNews
Surprising results show that phage join forces to overcome bacteria’s CRISPR -based immune defenses. Improved understanding of the interactions between phage and their bacterial hosts could help advance phage-based therapies and stimulate viral research.READ MORE
Study in Mouse Model of Autism Finds Mother's Microbiome Determines RiskNews
The microbiome is the collection of microorganisms, such as bacteria, that naturally live inside us. New research in a mouse model suggests the microbiome determines autism risk.READ MORE